General Information of Drug (ID: DMJNQE1)

Drug Name
PMID24749861C34 Drug Info
Synonyms GTPL8129; BDBM50013820
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
86290500
TTD Drug ID
DMJNQE1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ORIN1001 DM27RXS Metastatic breast cancer 2C6Y Phase 1/2 [2]
US9040714, 7 DM53Z4I N. A. N. A. Patented [3]
T8361 DM86BDS N. A. N. A. Patented [4]
US8614253, 29-1 DMJKFVU N. A. N. A. Patented [5]
US8614253, 32-5 DMSQODK N. A. N. A. Patented [4]
US8614253, 29-19 DMVI83P N. A. N. A. Patented [6]
879325-11-8 DMP04Z6 N. A. N. A. Patented [3]
AC1LE05K DMPOR3G N. A. N. A. Patented [7]
US8614253, 32-4 DMRSP2M N. A. N. A. Patented [6]
BB 0223767 DM2DT6L N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endoplasmic reticulum to nucleus signaling 1 (ERN1) TTOJ9QL ERN1_HUMAN Inhibitor [1]

References

1 Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. J Med Chem. 2014 May 22;57(10):4289-301.
2 Clinical pipeline report, company report or official report of Orinove.
3 IRE-1 inhibitors. US9040714.
4 IRE-1 inhibitors. US8614253.
5 IRE-1 inhibitors. US9241942.
6 IRE-1 inhibitors. US9493435.
7 IRE-1 inhibitors. US9693992.